Comparative cardiovascular safety with janus kinase inhibitors and biological disease-modifying antirheumatic drugs as used in clinical practice: an observational cohort study from Sweden in patients with rheumatoid arthritis

Figures

• 

  Figure 1. Kaplan-Meier failure function for time-to-major acute cardiovascular event in patients with rheumatoid arthritis treated with janus kinase inhibitor (JAKi), non-tumour necrosis factor inhibitor (TNFi) biological disease-modifying anti rheumatic drug (bDMARD) and TNFi, and general population comparators in Sweden. Note the reduced y-axis range.

• 

  Figure 2. HRs comparing janus kinase inhibitors (JAKis) and non-tumour necrosis factor inhibitor (TNFi) biological disease-modifying antirheumatic drug (bDMARDs) to TNFis for rates of major acute cardiovascular (CV) event in patients with rheumatoid arthritis in Sweden. Estimated from Cox proportional hazards models adjusting for age, sex, number of previous biological therapies, disease history, concomitant therapies, disease-related factors, smoking and socioeconomic factors. Main analyses, subgroup analyses restricted to a CV-enriched population, estimates by previous number of b/tsDMARDs, and estimates where the HR could vary over time-since treatment initiation.

• 

  Figure 3. HRs comparing janus kinase inhibitors (JAKis) and non-tumour necrosis factor inhibitor (TNFi) biological disease-modifying antirheumatic drug (bDMARDs) to TNFis for rates of major acute cardiovascular event in patients with rheumatoid arthritis in Sweden. Estimated from flexible parametric survival models allowing for non-proportional hazards and adjusted for age, sex, number of previous biological therapies, disease history, concomitant therapies, disease-related factors, smoking and socioeconomic factors.